DURHAM, N.C., June 16, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that Jeff Abbey, president and CEO, will present at the 2015 JMP Securities Life Sciences Conference on Tuesday, June 23rd, at 10:00 a.m. Eastern Time. Mr. Abbey will discuss the AGS-003 clinical development program, including the pivotal ADAPT phase 3 trial, as well as the AGS-004 program. Mr. Abbey and Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development, will be available to participate in one-on-one meetings with registered attendees. The conference will be held at The St. Regis Hotel in New York, NY.
A live audio webcast of the presentation can be accessed via the Investors section of the Company's website at www.argostherapeutics.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 14 days following the presentation.
About Argos Therapeutics
Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial aimed at HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com.
Source:Argos Therapeutics, Inc.